Atara Biotherapeutics Inc. (ATRA)
NASDAQ: ATRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ATRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $64.49M
- Forward P/E
- 3.96
- EPS (TTM)
- -$1.12
- Dividend yield
- None
- 52-week range
- 3.92 – 19.15
- Day range
- 6.25 – 6.85
- Volume / Avg
- 36.42K / 35.46K
- Beta
- —
- Shares outstanding
- 10.19M
52-week range
ATRA stock today
On Nov 20, ATRA ended the session at $6.33, shedding $0.01 (0.16%), versus the S&P 500's 3.70% decline. At this level, ATRA sits near the bottom of its 52-week range of $3.92 to $19.15: 66.9% below the high, set on Jan 5, 2026 and 61.5% above the low. ATRA is down 65.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.7%.
Atara Biotherapeutics has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Atara Biotherapeutics
Company profileAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Anhco Nguyen Ph.D.
- Headquarters
- Thousand Oaks, CA
- Employees
- 10
- IPO year
- 2014
- Website
- atarabio.com
Financial highlights
Full financialsIn fiscal 2025, Atara Biotherapeutics generated $120.8 million in revenue, down 6.3% from fiscal 2024, its first annual decline since 2023. Net income was $32.7 million, for a net margin of 27.1% versus a median of -359.1% in the prior 5 years. Operating margin was 29.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $120.77M | $128.94M | $8.57M | $63.57M | — |
| Growth | -6.33% | +1404.02% | -86.51% | — | — |
| Net income | $32.69M | $-85.40M | $-276.13M | $-228.30M | $-340.14M |
| EPS (diluted) | $2.57 | $-11.41 | $-65.19 | $-2.24 | $-3.63 |
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$13.67+115.96%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.15 vs —
ATRA news
All ATRA newsAtara Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TNYATenaya Therapeutics Inc. | 0.2866 | -3.99% | $65.32M | vs ATRA |
| NMRANeumora Therapeutics Inc. | 0.3339 | -3.78% | $63.01M | vs ATRA |
| CRDFCardiff Oncology Inc. | 0.8528 | -4.46% | $66.34M | vs ATRA |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs ATRA |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs ATRA |
| OKYOOKYO Pharma Limited | 1.07 | -7.76% | $56.15M | vs ATRA |
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs ATRA |
| AVXLAnavex Life Sciences Corp. | 0.5915 | -11.39% | $54.83M | vs ATRA |
Indexes, lists and sector
Atara Biotherapeutics stock FAQ
What is Atara Biotherapeutics's stock price today?
ATRA last traded at $6.33 as of Nov 20, 4:00 PM EST, down 0.16% on the day. Prices are delayed at least 15 minutes.
Does Atara Biotherapeutics pay a dividend?
No. Atara Biotherapeutics does not currently pay a regular cash dividend.
Who is Atara Biotherapeutics's CEO?
Dr. Anhco Nguyen Ph.D. is the chief executive officer of Atara Biotherapeutics Inc., which has about 10 employees.
Has ATRA ever split its stock?
Yes. The most recent ATRA stock split was a 1-for-25 split on Jun 20, 2024.
What is the ATRA 52-week high?
The 52-week high for ATRA is $19.15 and the 52-week low is $3.92. The stock is currently 66.9% below its high.